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Abstract 
A liquisolid system has the ability to improve the dissolution properties of poorly 
water soluble drugs. Liquisolid compacts are flowing and compactable 
powdered forms of liquid medications. The aim of this study was to enhance the 
in vitro dissolution properties of the practically water insoluble loop diuretic 
furosemide, by utilising liquisolid technique. Several liquisolid tablets were 
prepared using microcrystalline cellulose (Avicel® pH-101) and fumed silica 
(Cab-O-Sil® M-5) as the carrier and coating materials, respectively. Polyoxy-
ethylene-polyoxypropylene-polyoxyethylene block copolymer (Synperonic® 
PE/L 81); 1,2,3-propanetriol, homopolymer, (9Z)-9-octadecenoate (Caprol® 
PGE-860) and polyethylene glycol 400 (PEG 400) were used as non- volatile 
water-miscible liquid vehicles. The liquid loading factors for such liquid vehicles 
were calculated to obtain the optimum amounts of carrier and coating materials 
necessary to produce acceptable flowing and compactible powder admixtures 
viable to produce compacts. The ratio of carrier to coating material was kept 
constant in all formulations at 20 to 1. The formulated liquisolid tablets were 
evaluated for post compaction parameters such as weight variation, hardness, 
drug content uniformity, percentage friability and disintegration time. The in-vitro 
release characteristics of the drug from tablets formulated by direct 
compression (as reference) and liquisolid technique, were studied in two 
different dissolution media. Differential scanning calorimetry (DSC) and Fourier-
Transform infrared spectroscopy (FT-IR) were performed.The results showed 
that all formulations exhibited higher percentage of drug dissolved in water (pH 
6.4–6.6) compared to that at acidic medium (pH  1.2). Liquisolid compacts 326 B.  Akinlade  et al.:  
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containing Synperonic® PE/L 81 demonstrated higher release rate at the 
different pH values. Formulations with PEG 400 displayed lower drug release 
rate, compared to conventional and liquisolid tablets. DSC and FT-IR indicated 
a possible interaction between furosemide and tablet excipients that could 
explain the dissolution results. Caprol® PGE-860, as a liquid vehicle, failed to 
produce furosemide liquisolid compacts.  
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Introduction 
The solubility of active ingredient(s) is a matter of concern to formulators. The poor 
dissolution rates of poorly water soluble drugs is still a substantial problem confronting 
drug development, such as hindering the development of parenteral products and limiting 
the bioavailability of oral products [1]. Poorly soluble drugs that are administered orally will 
generally exhibit slow dissolution rates and incomplete bioavailability due to poor 
wettability of those drugs. This indicates that drugs are not sufficiently wetted before 
reaching absorption site [2]. From a physicochemical point of view, it is well established 
that the inadequate dissolution of poorly water soluble drugs is the major reason for their 
poor and erratic bioavailability, since it is the rate determining step in the absorption of 
those drugs.  
As large proportions of new drug candidates have poor aqueous solubility, various 
formulation strategies were reported to overcome such a problem. Among these 
techniques is complexation with cyclodextrins, solid dispersion, co-precipitation and 
recently, the technique of ‘liquisolid compacts’. Several studies have shown that the 
liquisolid technique is a promising method for promoting dissolution rate of poorly water 
soluble drugs [3–9]. In liquisolid compact, a liquid medication is converted into acceptably 
flowing and compactible powder forms. The term ‘liquid medication’ implies liquid lipophilic 
(oily) drug and solution or suspension of poorly water soluble drugs carried in suitable 
water miscible non-volatile liquid systems termed the liquid vehicle. By simple blending 
with suitable excipients ‘carrier and coating materials’, the liquid medication may be 
converted into a dry-looking, non-adherent, free flowing and readily compactible powder 
[10]. Since drug dissolution is often the rate limiting step in gastrointestinal absorption, the 
significant increase in wetting properties and surface area of drug particles available for 
dissolution from liquisolid compacts may be expected to display enhanced drug release 
characteristics and, consequently, improved oral bioavailability. 
The technique of liquisolid compacts has been successfully employed to improve the in 
vitro release of poorly water soluble drugs such as carbamazepine [11], famotidine [12], 
piroxicam [5], indomethacin [6], hydrocortisone [3], naproxen [8] and prednisolone [10].  
Furosemide, 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid, is a drug with a 
diuretic action which acts at the renal level on the ascending limb of the loop of Henle, and 
is used in the treatment of oedema of pulmonary, cardiac or hepatic origin as well as in the 
treatment of hypertension and in the chronic treatment of cardiac infarction [13]. The major 
problem associated with the formulation and effectiveness of the furosemide is its variable   Liquisolid Systems to Improve the Dissolution of Furosemide  327 
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oral absorption of about 11–90% [14] due to insufficient aqueous solubility at 
gastrointestinal pH, thus making solubility the rate-determining step in the gastric 
absorption of furosemide [15]. Therefore, furosemide establishes a good candidate for 
testing the potential of rapid-release liquisolid compacts 
The aim of this study was to increase dissolution rate of furosemide using liquisolid 
technique. The drug was formulated into 20 mg liquisolid tablets using Synperonic® PE/L 
81, Caprol® PGE-860 and PEG 400 as the water miscible non-volatile liquid vehicles. 
Theoretical model of liquisolid systems [4] was used to calculate the appropriate quantity 
of excipients (carrier and coating materials) for each liquid vehicle required to produce 
acceptably flowing and compactible powders. The liquisolid powder system which showed 
acceptable flowability was then compacted into tablets and the in vitro drug dissolution 
rates of liquisolid formulations were compared to that of conventional, directly compacted 
tablets. There is no single non-volatile liquid vehicle which is suitable for a variety of 
hydrophobic drugs in preparing liquisolid tablets. Propylene glycol, Tween 80 and 
polyethylene glycol 400 (PEG400) had been used as non-volatile liquid vehicles in the 
preparation of fast release liquisolid tablets with different drugs [4, 6, 7, 10, 14]; El-Gizawy 
[16] reported that polysorbate 80 shows better dissolution rate than propylene glycol and 
PEG400 when used with meloxicam. From the other hand, Spireas and Sadu [10]; 
Nokhodchi et al. [6] reported that liquisolid tablets containing propylene glycol show higher 
dissolution rate than those containing PEG400 or polysorbate 80. Accordingly in this study 
besides PEG400, Caprol® PGE-860 and Synperonic® PE/L 81, which have not, to the 
best of our knowledge, been studied before to enhance dissolution of furosemide, were 
used as non-volatile liquid vehicles in the liquisolid systems containing furosemide to 
enhance its dissolution. 
Results and Discussion 
Solubility measurement 
The solubility of furosemide in the non-volatile liquid vehicles, Synperonic® PE/L 81, 
Caprol® PGE 860, PEG 400 as well as water was determined. The results showed greater 
solubility of the drug in all vehicles in comparison to water. The amounts (µg/ml) of 
furosemide dissolved were 4.47 ±1.2, 34.6 ±2.6, 42.3 ±3.1 and 46.0 ±2.9 in water, PEG 
400, Synperonic® PE/L 81 and Caprol® PGE 860, respectively. The higher solubility of the 
drug in Caprol® PGE 860 compared with other liquid vehicles may be due to the longer 
non-polar chain of Caprol® PGE 860. The longer non-polar part is thought to reflect 
hydrophobic interactions of the drug with the liquid vehicle molecule [16].  
Flowable liquid retention potentials (Ф-values) and liquid load factors (Lf) for 
Avicel® PH 101 and fumed silica  
The optimum angle of slide for both carrier and coating materials were determined in order 
to calculate the optimum liquid loading factor (Lf) for each of them in Syperonic® PE/L 81 
and Caprol® PGE 860 (as discussed in Experimental Section, see below). The angle of 
slides for the carrier and coating materials alone and in the presence of different 
concentrations of the liquid vehicles are graphically presented in Figures (1 and 2). As a 
general trend, the angle of slide for both carrier and coating materials increased as the 
flowable liquid retention potentials increases. 328 B.  Akinlade  et al.:  
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The flowable liquid retention potentials (ФCA-value) for Avicel® PH 101 in Synperonic® 
PE/L 81 and Caprol® PGE 860 corresponding to an angle of slide of 33º were 
approximately 0.164 and 0.76, respectively.  
For fumed silica, the flowable liquid retention potential (ФCO-value) in Synperonic® PE/L 
81 corresponding to an angle of slide of 33° was equal to approximately 2.20. However, 
the angle of slide of silica in Caprol® PGE 860 (28.98°) was below 33° (Figure 2). 
Furthermore, any increase in ФCO-value more than 1.55 resulted in decreasing the angle 
of slide. As a result, the angle closet to 33° was chosen “which corresponded to a resultant 
ФCO-value of 1.55”. Flowable liquid retention potential values for Avicel® PH 101 and 
fumed silica in PEG 400 were taken from literature [4]. The Liquid load factors (Lf) were 
then calculated using Equation (1). For each non-volatile liquid vehicle, the corresponding 
Lf value is presented in Table (2). 
Percentage compressibility studies of different powder systems  
Powder flow is a critical character that might affect uniformity of tablet weight. Therefore, 
the flow properties of the powder admixture of conventional and liquisolid formulations 
were determined in order to ensure that the amount of carrier and coating materials are 
enough to maintain acceptable flow and compaction properties. The Carr’s index (CI%) or 
percentage compressibility were calculated for conventional and liquisolid powder 
admixtures. Previous studies have shown that in preparation of liquisolid tablets, it is 
difficult to prepare formulations with good flowability and compactibility when liquid loading 
factor is significantly above 0.25 [5]. The liquid load factors for PEG 400, Synperonic® 
PE/L 81 and Caprol® PGE 860 were 0.168, 0.274 and 0.8375, respectively (Table 2). The 
liquid load factor for Caprol® PGE 860 was approximately 3 times greater than 0.25. The 
prepared powder admixtures LS-5 and LS-6 (with Caprol® PGE 860) showed poor 
flowability and were not compactible. In addition, those powder admixtures were in the 
form of aggregates with some segregation noticed during powder mixing, whilst the 
powders for the remaining liquisolid formulations appeared fine (LS-1 to LS-4). Such 
behaviour of LS-5 and LS-6 powder systems could possibly coincides with high liquid load 
factor of Caprol® PGE 860, and indicates poor flowability. Other explanation for this failure 
could be based on the viscosity of the liquid vehicle as it was stated that the viscosity of 
the vehicles affects the flowability of powders [17].  
Tab. 3.  Characteristics of the formulated furosemide tablets. 
Batch 
code
a 
Average furosemide 
contents (% ±SD)  
% Friability  Hardness  
(N ±SD)  
Disintegration 
Time  
(min ±SD)  
CDT 
LS-1 
LS-2 
LS-3 
LS-4 
  97.32 (± 1.7) 
  99.91 (± 1.5) 
100.03 (± 3.7) 
100.02 (± 2.8) 
101.02 (± 1.7) 
1.40 
0.51 
0.32 
0.14 
0.22 
 27.4  (± 9.64) 
 39.4  (± 7.99) 
  46.9 (± 11.6) 
 98.1  (± 8.19) 
107.9 (± 12.7) 
0.82 ± 0.34 
0.35 ± 0.16 
0.27 ± 0.11 
19.3 ± 2.1 
22.5 ± 1.6 
a for the composition of each formula refer to Table 1. 
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The dynamic viscosity of PEG 400, Synperonic® PE/L 81 and Caprol® PGE 860 were 
measured (See Section 2.4) and found to be 111.3, 454, and 5276 mPas, respectively. 
Therefore, it could also be suggested that the poor flowability of powder prepared using 
Caprol® PGE 860 is due to its high viscosity which may hindered powder mixing. 
Therefore, liquisolid formulations LS-5 and LS-6 were considered as unsuccessful and will 
not, therefore, be considered further in our discussion.  
For the conventional tablets, and the liquisolid formulations, CI% values were 19.6 ±2.6%, 
4.8 ±0.64%, 18.6 ±2.1%, 13.6 ±1.5%, and 20 ±1.7% for CDT, LS-1, LS-2, LS-3 and LS-4, 
respectively. It was stated that powder showing compressibility index between 5 and 15% 
is considered to have excellent flowability, whilst CI% values between 12 and 16% is of 
good flowability and up to 21 is fair to passable [18]. Therefore, we can say that CI% 
values of all liquisolid powder admixtures were less than (P < 0.05) that of conventional 
powder system, except formula LS-4 that showed a similarity (P > 0.05) to the con-
ventional type. Therefore, such decrease in compressibility index would indicate 
substantial improvement in flow and packing ability of the powder mass of liquisolid 
formulations in comparison to the conventional type. The reason for flow improvement of 
liquisolid formulations can be attributed to use of the appropriate amounts of Avicel® PH 
101 and fumed silica as calculated by applying Equations 1–3, accordingly non-adherent 
and free flowing powders were produced. The overall results reflect that all tested powder 
systems have acceptable flowability that would suggest a uniform and reproducible die 
filling resulting in tablets of uniform weights upon compression.  
Tab. 4.  The total amount of drug released after 10 minutes (DR10min) and the time 
necessary to release 50% of the drug from different formulations at different 
dissolution media. 
0.1N HCl (pH1.2)  Distilled water (pH 6.4-6.6)  Formula 
Code
a  DR10min  
(% ±SD) 
T50%  
(min ±SD) 
DR10min  
(%±SD) 
T50%  
(min ±SD) 
DCT 
LS-1 
LS-2 
LS-3 
LS-4 
24 (±2.1) 
34 (±3.1) 
40 (±1.9) 
0.9 (±0.51) 
2.2 (±0.92) 
>60 
50 (±3.5) 
20 (±2.8) 
>60 
>60 
57 (±3.2) 
52 (±3.6) 
64 (±2.7) 
1.3 (±0.71) 
2.9 (±1.1) 
10 (±1.2) 
8.0 (±1.4) 
6.0 (±1.3) 
>60 
59 (±4.8) 
a for the composition of each formula refer to Table 1. 
 
Evaluation of furosemide liquisolid (LS-1 to LS-4) and conventional (DCT) tablets 
Table 3 shows the results of tests performed to evaluate the physical properties of the 
prepared tablets according to British Pharmacopoeia [19].  
It is clear that conventional (CDT) and liquisolid tablets complied with the required 
specifications and standard regarding drug content uniformity. Liquisolid tablets complied 
with British Pharmacopeia friability test as the friability was less than 1% and there were 
no broken tablets, whilst conventional tablets (Table 3) exhibited percentage friability more 
than 1% (not comply with the British Pharmacopeia specification). Therefore, conventional 
tablets could not withstand fracturing and attrition during normal handling and transport. 330 B.  Akinlade  et al.:  
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For the disintegration time results, CDT, LS-1 and LS-2 showed very short disintegration 
time (few seconds), while that for LS-3 and LS-4 was prolonged. The rapid disintegration 
of CDT might be due to tablet friability as it showed the highest percent friability and less 
cohesion compared to all other formulations (Table 3). For LS-1 and LS-2, though showed 
acceptable friability and tablet cohesion, they displayed rapid disintegration. This could be 
due to the surface activity of Synperonic® PE/L 81 that would facilitate tablet wetting by 
reducing the interfacial tension. On the other hand, PEG 400, with its two terminal hydroxyl 
groups, may strengthen the binding of the tablet by the formation of hydrogen bonding with 
Avicel® PH 101 (as will be confirmed by FT-IR data), thus conferring cohesion to the 
compacts as reflected by the hardness results (Tab 3). This might resulted in prolongation 
of the tablet disintegration times that would, therefore, affect tablet dissolution [12]. 
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Fig. 3.  Dissolution profiles of furosemide from conventional and liquisolid tablets at: (A) 
pH 1.2 using 0.1N HCl and (B) pH 6.4-6.6 using distilled water.    Liquisolid Systems to Improve the Dissolution of Furosemide  331 
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In vitro dissolution studies 
Dissolution profiles of furosemide batches in water (pH 6.4-6.6) and 0.1N HCL (pH 1.2) are 
presented as the percentage drug released versus time plots (Figure 3A and B). The 
percentage drug released after 10 minutes (DR10min) and half life values T50% (i.e. time 
required to dissolve 50% of the drug) were calculated and are collected in Table 4. The 
total percentages of drug dissolved at the end of the dissolution experiment are presented 
as histograms in Figure 4. 
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Fig. 4.  Total amount released of furosemide from conventional and liquisolid tablets 
using different dissolution media, for compositions refer to Table 1. 332 B.  Akinlade  et al.:  
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In the acidic medium (pH 1.2), liquisolid formulations prepared with Synperonic® PE/L 81 
as the liquid vehicle showed higher drug dissolution, compared to CDT and liquisolid 
containing PEG 400 (Figure 3A). Such formulations showed DR10min of 34, 40 and 12% for 
LS-1, LS-2 and CDT, respectively. Meantime, T50% was 50 and 20 minutes for LS-1 and 
LS-2, respectively, while that for CDT was out of the range of the experiment time. For 
liquisolid compacts prepared using PEG 400, DR10min were 0.3 and 1.2% for LS-3 and LS-
4, respectively, with T50% of more than 60 minutes. Generally, the higher liquid vehicle to 
drug ratio of 4:1 (LS-2 and LS-4) showed a significant (P < 0.05) increase in drug 
dissolution compared to the lower liquid vehicle:furosemide ratio of 2:1 (LS-1 and LS-3). 
The high amount of the liquid vehicle in the higher ratio may have resulted in more of 
furosemide present in the molecular dispersion state or more drug solubilised in the liquid 
vehicle as will be explained by the DSC data (See Section 3.6). Furthermore, this could be 
explained on the basis that after tablet disintegrated, the liquisolid primary particles 
suspended in the dissolution medium partly in the molecular dispersion state, therefore the 
surface area of drug available for dissolution is much greater in LS-2 and LS-4 (more 
wetted with the liquid vehicle; giving rapid dissolution due to reduced lipophilicity of the 
particles) to that of furosemide particles of conventional tablets; this explanation is in 
agreement with Spireas and Sadu [10]. The unexpected lower dissolution of liquisolid 
compacts prepared with PEG 400 could be attributed to the fact that furosemide was more 
soluble in Synperonic® PE/L 81 (See solubility section, 3.1) than in PEG400. If the drug is 
more soluble in one vehicle compared to another, the more solute molecule will be in the 
molecular dispersion state in the former vehicle. Consequently, the more drug dissolved in 
Synperonic® PE/L 81 will be adsorbed on coating material (fumed silica) thus exposing 
more drug to the dissolution media and higher dissolution occur (Figure 3). For the 
remaining un-dissolved drug particles, mixing with Synperonic® PE/L 81, being a non-ionic 
surfactant, may result in a greater wetting and reduction in the interfacial tension between 
the drug particles and the dissolution media leading to increased drug particle surface area 
in contact with dissolution media and subsequent improvement in drug solubility. Other 
possible explanation for the lower dissolution from liquisolid compacts with PEG 400 could 
be due to the poor disintegration and the high tablet hardness as explained earlier (See 
section 3.4). The interaction between the drug with the vehicle could be a possibility for 
these results, therefore characterisation of the systems was performed using thermal 
analysis and infrared spectroscopy (See below). 
On performing the dissolution study using distilled water (Fig. 3B), all formulations 
displayed higher drug dissolution compared to that at 0.1N HCL. In case of formulations 
using Synperonic® PE/L 81 as a liquid vehicle (LS-1 and LS-2), there was a significant (P 
< 0.05) difference in percentage drug released compared to liquisolid compacts prepared 
with PEG400 (LS-3 and LS-4). In addition, the total amount of the drug dissolved from LS-
1 and LS-2 at the end of the dissolution was significantly high (P < 0.05) compared to that 
from conventional tablets, CDT (Fig. 3B). The DR10min and T50% values for LS-1, LS-2 and 
CDT in distilled water were higher than those in the acidic medium. For drug dissolution 
from PEG 400 formulations in distilled water still inferior to that of Synperonic PE/L 81 
liquisolid compacts as well as conventional tablets. Again, compacts with higher 
vehicle:drug ratio of 4:1, showed a significant (P < 0.05) increase in drug dissolution. The 
higher drug dissolution at the higher pH value could be due to the fact that furosemide is a 
weak acidic drug with pKa value of 3.9 [20]. In distilled water, where pH value (ranged from   Liquisolid Systems to Improve the Dissolution of Furosemide  333 
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6.4 to 6.6) is higher than drugs’ pKa, the carboxylic group of furosemide will be highly 
ionised and consequently drug solubility increases. 
Differential Scanning Calorimetry (DSC) 
In a trial to explain the dissolution data, thermal analysis was conducted to establish the 
existence of any possible interaction between the drug and tablet excipients. 
Thermograms of furosemide test systems are shown in Figure 5.  
(a) 
 
(b) 
Fig. 5.  DSC thermograms of (a) furosemide and (b) pure excipients and furosemide 
whithin conventional and liquisolid formulations where b1 (pink line) is potato 
starch, b2 is Avicel® PH 101 (green line), b3 (black line) is conventional 
powder, b4 (dark red line) is LS-1, b5 (faint blue line) is LS-3 and b6 (dark blue 
line) is fumed silica. For compositions refer to Table 1. 
b1 
b3 
b2 
b4 
b5 
b6 334 B.  Akinlade  et al.:  
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Furosemide alone exhibited a characteristic, sharp peak at 223.7°C, which indicates its 
crystalline nature. It is known that disappearance or shifting of endo-or exothermic peaks 
is an indication of change in crystalline structure of the drug. In conventional formulation, 
CDT, there was shifting in the furosemide characterstic peak to lower temperature (217°C) 
with reduction in enthalpy indicating reduced drug crystallinity. In the case of LS-1 
(Figure 5) and the same for LS-2 (data not shown), there were complete disappearance of 
furosemide characteristic peak, indicating complete loss of crystallinity or amorphisation of 
the drug that could explain the improved drug dissolution over conventional type. For PEG 
400 liquisolid compacts (Figure 5), furosemide characteristic peak was not found indicating 
amorphisation, with a slight shift in the endothermic peak of Avicel® PH 101 with reduced 
enthalpy, indicating complete solubilisation and/or dispersion of the drug in the liquid 
vehicles forming uniform dispersion in the carrier with a possible formation of a complex. 
The formation of this complex could be the reason for poor dissolution of furosemide from 
these formulations. Therefore, FT-IR study was conducted to investigate the possible 
interaction between the drug and the other components of the tablets.  
Fourier Transform Infrared Spectroscopy 
FT-IR was performed for the pure drug and liquisolid powders to detect any sign of 
interaction which would be reflected by a change in the position or disappearance of any 
characteristic stretching vibration of the compound. From the infrared spectrum of pure 
furosemide, absorption bands are observed at 3340 and 3260 cm
−1 and sharp bands are 
observed at 1665 and 1560 cm
−1 (Figure 6). The 3340 cm
−1 band is assigned to the NH2 
stretching vibration of Ar---NHCH2 and the 3260 cm
−1 band is assigned to stretching 
vibration of SO2NH2 and the 1665 cm
−1 band, which appears at such high frequency 
region, is assigned to the bending vibration of amino group. The 1560 cm
−1 band is due to 
the assymmetric stretching vibration of the carbonyl group and the 1318 cm
−1 band is 
assigned to the assymmetric stretching vibration of the sulfonyl group in the furosemide 
structure [21–22].  
In the case of liquisolid formulations containing Synperonic® PE/L 81 (LS-1 and LS-2), all 
peaks of the drug still shown in the spectrum indicating that there was no interaction 
between the drug and the vehicle and the drug was molecularly dispersed in the liquid 
vehicle, confirming the DSC data. Nevertheless, for liquisolid formulations containing PEG 
400 (LS-3), it is clear from the spectrum that there was a change in the spectrum 
compared to that of pure furosemide (decreased intensity of most peaks in addition to 
disappearance of some characteristic bands of the drug, e.g. peak corresponds to the 
stretching vibration of the sulfonyl group at 1318 cm
−1). Also, the peaks for imino- and 
sulfonylamide vibrations were disappeared and replaced by a broad peak. These results 
would strengthen our previous assumption that interaction such as association between 
functional groups of furosemide and PEG 400 at the molecular level had occurred resulting 
in formation of a complex that was less soluble than the parent compound. The 
association between furosemide and PEG 400 is expected to be most probably between 
the imino group and the sulfonylamide group of furosemide and the terminal hydroxyl 
groups of PEG400. 
   Liquisolid Systems to Improve the Dissolution of Furosemide  335 
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Fig. 6.  FT-IR spectra of furosemide and liquisolid formulations: LS-1 and LS-3. For 
compositions refer to Table 1. 
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Conclusion 
From the conducted work it is possible to conclude that, based on the nature of the drug 
and the non-volatile liquid vehicle used, liquisolid technique has the capability to increase 
furosemide intrinsic solubility. Liquisolid tablets containing Synperonic® PE/L 81 as a new 
liquid vehicle exhibited greater dissolution due to the physical properties of this liquid 
vehicle which led to increased wetting properties and solubility of the drug; demonstrating 
higher drug release than those of conventionally made tablets (which failed as well friability 
test and could not withstand). PEG 400 as a liquid vehicle failed to improve furosemide 
dissolution owing to lower solubility of the drug in PEG 400 compared to Synperonic® 
PE/L 81 and possible drug-PEG 400 interaction as revealed by DSC and FT-IR data. 
Since drug dissolution is the rate limiting step in oral drug absorption of non-polar 
molecules, liquisolid compacts prepared with Synperonic® PE/L 81 might present 
substantial in vivo superiority over conventional directly compacted counterpart. Caprol® 
PGE 860 was not a good choice of liquid vehicles to prepare furosemide liquisolid tablets. 
There is no single liquid vehicle which is suitable for all poorly water soluble drugs to 
formulate liquisoid compacts. Accordingly, choosing a suitable liquid vehicle, depending on 
its properties e.g. viscosity, for a particular drug is important to prepare a successful 
liquisolid tablets. 
Experimental 
Materials 
Furosemide was provided by Sigma-Aldrich Company Ltd (Gillingham UK). 
Microcrystalline cellulose (Avicel® PH101) (FMC Corp., Philadelphia, USA), colloidal 
silicon dioxide (Cab-o-sil® M-5, fumed silica) (Cabot Corporation, Rheinfelden, Germany), 
potato starch (BDH laboratory supplies, Poole, England), 1,2,3-propanetriol, homopolymer, 
(9Z)-9-octadecenoate (Caprol® PGE-860) (Abitec Corporation, Columbus, USA), 
Synperonic® PE/L 81 (polyoxyethylene-polyoxypropylene-polyoxyethylene block 
copolymer) (ICI surfactants, Everberg, Belgium) and polyethylene glycol 400 (PEG 400) 
(BDH laboratory supplies, Poole England) were used. Other reagents were of analytical 
grade.  
Theoretical aspects for designing the liquisolid systems 
The amounts of excipients (carrier and coating materials) used to prepare liquisolid 
compacts depend on the flowable liquid retention potential values (Ф-value) and the liquid 
loading factors (Lf), Equation 1. The Ф-value of a powder is the maximum amount of a 
given non-volatile liquid that can be retained inside powder bulk (w/w) while maintaining 
acceptable flowability. Whereas, Lf is the mass ratio (w/w) of the liquid medication to the 
carrier powder in the liquisolid formulation, and it is given by Equation 2. Therefore, in 
order to calculate the required weight of excipients, we need to determine the liquid 
retention potential value for both carrier (ФCA-value) and coating (ФCO-value) materials 
for each non-volatile liquid vehicle used, these values are constant for the given 
vehicle/powder system. Knowing the carrier:coating ratio (R), which is 20:1 in this study, 
liquid loading factor (Lf) can be calculated by the following equation: 
Eq. 1.  
R
1
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Once liquid loading factors were obtained for such non-volatile liquid vehicle used in this 
study, the optimum weight of the carrier (Q), required for the respective vehicle could be 
calculated by rearranging the Equation (2). 
Eq. 2.  
Q
W
    Lf =  
Where: W is the weight of the liquid medication (the drug + non-volatile liquid vehicle) and 
Q is the weight of the carrier [7, 9]. The weights of the liquid medications (the drug + non 
volatile liquid vehicle) were calculated at drug:vehicle ratios of 1:2 and 1:4. Once the 
values for Q were obtained for the respective vehicle, the optimum weight of the coating 
material (q) could also be obtained (Equation 3). 
Eq. 3.  
q
Q
    R =  
Where: Q and q are the weight of the carrier and coating material, respectively.  
According to the theories of Spireas and his co-workers [4, 8, 21], the carrier and coating 
powder materials can retain only certain amount of the liquid vehicle while maintaining 
acceptable flow and compaction properties. The amounts of the drug, carrier and coating 
materials required to produce sixty tablets were then calculated and powders were 
prepared. The outline of the constituents of each of the formulation prepared from the 
previously mentioned variables are demonstrated in Table 1. 
Tab. 1.  Summary of the prepared liquisolid formulations. 
Liquisolid 
Formulation code 
Liquid vehicle  Drug:vehicle ratio 
LS-1 
LS-2 
LS-3 
LS-4 
LS-5 
LS-6 
Synperonic® PE/L 81 
Synperonic® PE/L 81 
PEG 400 
PEG 400 
Caprol® PGE 860 
Caprol® PGE 860 
1:2 
1:4 
1:2 
1:4 
1:2 
1:4 
 
Solubility Studies 
To determine the best non-volatile liquid vehicle for dissolving or suspending furosemide in 
liquid medication, the solubility of furosemide in Synperonic® PE/L 81, PEG 400, Caprol® 
PGE 860 and water was determined. Excess furosemide was added to 5ml of each liquid 
vehicle and was shaken in a shaker (Stuart Company Ltd, England) for 72 hours at 25°C 
under constant vibration. After this period, aliquots were taken, filtered through 0.45μm 
Millipore filter, diluted with distilled water and analysed by UV-Vis Spectrophotometer 
(CE292, Cecil Instruments, Cambridge, UK) at 228 nm. Three determinations were carried 
out for each sample to calculate the solubility of furosemide in each vehicle. 
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Determination of the viscosity of different liquid vehicles 
Viscosities of the non-volatile liquid vehicles (Caprol® PGE-860, Synperonic® PE/L 81, 
PEG 400) were determined at 25°C using Ostwald U-tube (D22596) viscometer. The rate 
of flow of the liquid via the capillary was measured under the effect of gravity. 
Determination of angle of slide for Avicel®PH 101 (carrier material) and fumed silica 
(coating material)  
Powder flowability is of critical importance in production of solid pharmaceutical dosage 
forms in order to get a uniform feed as well as reproducible filling of tablet dies, otherwise, 
high dose variation will occur. In order to ensure the flow properties of the liquisolid 
systems to be compacted into tablet, the angle of slide for Avicel®PH 101 (carrier material) 
and fumed silica (coating material) were measured. Exactly weighted 10 g of the carrier or 
coating material were placed at one end of a metal plate with a polished surface. The plate 
was gradually raised until the plate made an angle (θ, angle of slide) with the horizontal 
plane at which the powder was about to slide over the polished surface [11]. An angle of 
slide of 33º corresponded to optimum flow [11].  
Determination of flowable liquid retention potential for Avicel® PH 101 (ФCA-value) 
and fumed silica (ФCO-value)  
An increasing amount of the non-volatile liquid vehicles (Synperonic® PE/L 81 or Caprol® 
PGE 860) were added to 10 g of Avicel® PH 101 or silica powder and mixed using pestle 
and a mortar to give powder admixtures. The carrier and coating materials adsorbed the 
liquid vehicle resulting in a change in material flow properties compared to pure powder of 
Avicel® PH 101 or silica powder previously measured (See section 2.5). At each 
concentration of the non-volatile liquid vehicle, the angle of slide was determined as stated 
previously (section 2.5). The corresponding flowable liquid retention potentials were 
calculated using the following equation: 
Eq. 4.  
solid   of   weight
liquid   of   weight
    value - Φ   =  
Then, the obtained Ф-values were plotted against the corresponding angle of slides. The 
Ф-value which corresponded to an angle of slide of 33° represented the flowable liquid 
retention potentials of powder admixture [23]. In cases where the Ф-value did not 
correspond to 33°, the highest Ф-value reached was chosen as the flowable liquid 
retention potential. Figures 1 and 2 show the results. The ФCA-value for Avicel® PH 101 
with PEG 400 and the ФCO-value for fumed silica with PEG400 were reported to be 0.005 
and 3.26, respectively [4].    Liquisolid Systems to Improve the Dissolution of Furosemide  339 
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Fig. 1.  Relationship between the angle of slide of Avicel® PH 101 and fumed silica with 
Synperonic® PE/L 81 as a liquid vehicle 
 
Fig. 2.  Relationship between the angle of slide of Avicel® PH 101 and fumed silica in 
Caprol® PGE 860 as a liquid vehicle 
 
Preparation and mixing of powders for conventional and liquisolid tablets 
A conventional formulation of furosemide, (denoted as CDT; conventional) was directly 
compacted into tablets, each containing 20 mg drug. In addition, each tablet contained 200 
mg Avicel® PH 101, 10 mg fumed silica and 10 mg potato starch (as a disintegrant); a 
batch of 60 tablets was mixed in a turbular mixer (Erweka, Germany) and compacted 340 B.  Akinlade  et al.:  
Sci Pharm. 2010; 78: 325–344. 
using a 10mm flat-faced punch and die set tabletting machine (type F3, Manesty Machine 
Ltd., Liverpool, UK).  
In the case of liquisolid formulations, from the obtained results of optimum ФCA-and ФCO-
values (optimum flowable liquid retention values for the carrier and coating materials, 
respectively) with each liquid vehicle, the optimum liquid load factors (Lf) were calculated 
using Equation (1) with carrier:coat ratio (R) of 20. Then, the amount of carrier (Q) and 
coating (q) materials were calculated using Equations 2 and 3 at drug:vehicle ratios of 1:2 
and 1:4. Several liquisolid systems of furosemide (LS-1 to LS-6; Table 1) were prepared in 
60 tablet batches of 20 mg strength each. The calculated amounts of the carrier (Q) and 
coating (q) materials at each liquid medication (W) are presented in Table 2.  
Accordingly, the liquisolid formulations were prepared as follows: the drug was suspended 
in the liquid vehicle in a mortar using pestle, then the calculated amount of the carrier 
material (Avicel® PH 101) was added with continuous mixing till homogenous wet mix is 
obtained. The coating material (fumed silica) was then added to the mix with gentle mixing 
(the powder admixture re-establish the dry powder consistency). Finally, each liquisolid 
formulation was blended with 5%w/w of a disintegrating agent (potato starch).  
Tab. 2.  Composition of different furosemide liquisolid formulations prepared using 
different liquid vehicles according to theoretical model by Spireas and 
Bolton [4]. 
Batch 
code
a 
Drug:liquid 
vehicle ratio 
W (mg)  Lf Avicel® 
PH 101 
(mg) 
(Q=W/ Lf) 
 Fumed 
silica 
(mg) 
(q=Q/R) 
Potato 
starch 
(mg) 
Unite 
dose 
weight 
(mg) 
LS-1 
LS-2 
LS-3 
LS-4 
LS-5 
LS-6 
1:2 
1:4 
1:2 
1:4 
1:2 
1:4 
 60 
100 
 60 
100 
 60 
100 
0.274 
0.274 
0.168 
0.168 
0.837 
0.837 
218.98 
364.96 
357.10 
595.20 
 71.64 
119.40 
10.95 
18.25 
17.86 
29.76 
 3.51 
 5.90 
14.50 
24.16 
21.75 
36.25 
 6.76 
11.27 
304.40 
507.40 
456.71 
761.21 
141.91 
236.57 
W … weight of liquid medication (drug + liquid vehicle); Lf … liquid load factor; Q … weight of carrier 
material; q … weight of coating material; R … carrier:coat ratio which equals to 20:1.  
a for the composition of each formula refer to Table 1. 
 
Determination of flow properties of prepared powder admixtures: 
Before compaction liquisolid powder admixture into compacts it was necessary to study 
the flowability of these systems. Flowability was assessed from Carr’s compressibility 
Index (CI%). The CI was calculated from the poured (bulk) and tapped densities. Tapped 
density was measured by tapping fixed weight of the sample into 100 ml measuring 
cylinder several times using a tap density apparatus (J. Engelsmann A.G., Ludwigshafen, 
Germany) till a constant volume is obtained, where the powder is considered to reach to its 
most stable arrangement. Carr’s compressibility index was then calculated using the 
following Equation [24]:   Liquisolid Systems to Improve the Dissolution of Furosemide  341 
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Eq. 4.     100    
density   tapped
density   bulk density –    tapped
   %   CI   ⋅ =  
The smaller the value of the CI%, the superior the flow properties of the powder [11].  
Compaction of the prepared powder admixtures 
The liquisolid powder admixtures (LS-1-LS-4) were compacted into tablets (60-tablet 
batches) containing 20 mg furosemide per tablet using the previously mentioned tabletting 
machine. The compression force that applied was sufficient to produce acceptable tablet 
hardness. Formulations LS-5 and LS-6 (with Caprol® PGE 860 as a liquid vehicle) were 
not compactible. 
Evaluation of furosemide conventional and liquisolid tablets: 
Tablets were evaluated by performing quality control tests for uniformity of drug content, 
friability, disintegration, hardness as well as dissolution test. All tests were carried out in 
triplicates and according to compendial specifications [19].  
(1) Drug content uniformity of furosemide was determined by collecting a sample of 10 
tablets from each batch followed by a determination of the drug concentration in 
each tablet spectrophotometrically at 228 nm. The average drug content is 
calculated and the percentage drug content of the individual tablet should fall within 
specified limits in terms of percentage deviation from the mean.  
(2) Friability was determined using Copley friabilator (FRV 1000, Copley Scientific, 
UK), the percentage loss in tablet weight before and after 100 revolution of 20 
tablets were calculated and taken as a measure for friability.  
(3) Disintegration time; the time necessary to disintegrate 6 tablets of each tablet 
formulation was determined using disintegration tester (Manesty Machine Ltd., 
Liverpool, UK).  
(4) Hardness; It is a measure of the mechanical strength of a tablet using hardness 
tester (Model 2E/205, Schleuniger & Co., Switzerland). The mechanical strength of 
a tablet is associated with the resistance of a tablet to fracture or attrition.  
(5) In vitro dissolution studies; The USP dissolution apparatus II (Caleva Ltd. Dorset, 
UK) was used with 900 ml, to ensure sink conditions, of distilled water (pH range of 
6.4–6.6) and 0.1N HCL (pH 1.2) at 37±0.5°C; the apparatus was run at 100 rpm. 
Samples of the dissolution medium were withdrawn at a specified time intervals 
and compensated by fresh dissolution medium. Samples were properly diluted and 
furosemide concentrations were analysed spectrophotometrically at 228nm. The 
cumulative percentage drug released at each time interval was calculated and 
plotted against time. 
Differential scanning calorimetry (DSC) 
DSC thermograms of furosemide, Avicel® PH101, fumed silica, potato starch, 
conventional and liquisolid formulations were generated with a DSC Refrigerated Cooling 
System (Model Q1000, TA Instruments, UK). Tested samples were weighed and analysed 
hermetically in sealed aluminium pans. The instrument was calibrated with sapphire and 342 B.  Akinlade  et al.:  
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indium before running the samples. The samples were examined from 10°C to 235°C at 
scanning rate of 10°C/minute. 
Fourier Transferom Infrared Spectroscopy 
Infrared spectra of the samples (furosemide and liquisolid formulations) were obtained, 
using Perkin Elmer FT-IR system Spectrum BX series (Beaconsfield, Buckinghamshire, 
UK), in the frequency range of 4000–550 cm
−1 at 4 cm
−1 resolution. The technique utilised 
very small amount of each sample which directly loaded into the system. Spectrum BX 
series software version 2.19 was used to determine peak positions. 
Statistical analysis 
One-way ANOVA and Independent-samples T-test were applied if the variances in the 
groups are equal. If the variances are significantly different, Mann-Whitney Test was used. 
Results are statistically significant when P <0.05. 
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